Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
By M. Pfeffer, J. McMurray, E. Velazquez, J. Rouleau, L. Køber, A. Maggioni, S. Solomon, K. Swedberg, F. Van de Werf, Harvey D. White and 6 more. New England Journal of Medicine, 2003
2,440 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/f7ed945f22c9b3f4187dbbd8bdfe76020539b4be
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- T. Horwich
- Jeroen J. Bax
- Gerasimos Filippatos
- F. Cosentino
- Joshua A. Beckman
- Hani Jneid
- J. Januzzi
Citations in the corpus
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, background): “topril for the primary endpoint of total mortality in the subgroup of diabetic patients with myocardial infarction complicated by leftventricular systolic dysfunction.(104) In the Losartan Intervention For Endpoint reduction in hypertension study,(105) losartan was found to be superior to atenolol i”
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012, positive): “Conversely, the VALsartan In Acute myocardial iNfarction Trial compared valsartan alone (160 mg twice daily), full-dose captopril (50 mg three times daily), or both (80 mg twice daily and 50 mg three times daily).(281) Mortality was similar in the three groups but discontinuations were more frequent”
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008, result): “Mortality was similar in the three groups, but discontinuations were more frequent in the groups receiving captopril.(221) Therefore, valsartan in dosages as used in the trial represents an alternative to ACE-inhibitors in patients who do not tolerate ACE-inhibitors and have clinical signs of heart ”